Home / Concalls / Aether Industries Limited

Aether Industries Limited

Details

Aether Industries Ltd Q1 & FY2027-26 Earnings Call Highlights

Financials

Business Background

Founded in 2013 and headquartered in Surat, Gujarat, Aether Industries Ltd. is a fast-growing, technology-driven specialty chemical company. The company specializes in advanced intermediate products and fine specialty chemicals involving complex and differentiated chemistries across three business pillars: Large Scale Manufacturing (LSM), Contract Research and Manufacturing Services (CRAMS), and Contract / Exclusive Manufacturing (CEM). Operating multi-location, highly automated DCS manufacturing sites and state-of-the-art R&D centers, Aether serves global and domestic blue-chip customers across key end-user sectors, including pharmaceuticals, agrochemicals, material sciences, and oil & gas.

Q&A

Q: What was the financial performance for Q1 FY27?

A: The company reported a 27% year-on-year revenue increase to ₹3,266 million, with PAT growing 33% to ₹627 million.


Q: What is the strategic goal for the CRAMS and CM business models?

A: Management aims for Contract Research and Manufacturing Services (CRAMS) and Exclusive Manufacturing (CM) to contribute 70% or more of total revenue within the next few years.


Q: Can you elaborate on the new partnership with Dow Chemical?

A: Aether has launched a multi-year collaborative research program with Dow to develop indigenous manufacturing technologies for silicons, a market currently dominated by imports.


Q: How is the company positioning itself in the semiconductor market?

A: It is developing specialty monomers and coupling agents for advanced low-dielectric materials used in 5G and AI hardware, focusing on high-value, low-volume chemistry.


Q: What is the update on the 'Magnum' Site 5 expansion?

A: Phase 1 of Site 5 is online, with a total planned investment of ₹2,200 to ₹2,300 crores through FY30 to reach full operational capacity.


Q: What is the expected capex for the current fiscal year?

A: For FY27, the company anticipates a total capex of ₹3,000 to ₹3,500 million, primarily directed toward Site 5 and a new R&D center.


Q: What are the typical EBITDA margins for the CM vertical?

A: Management guides for consolidated EBITDA margins between 28% and 30% for the CM business segment, which they consider margin-accretive.


Q: Why was there a decline in Large Scale Manufacturing (LSM) volumes?

A: The 22.5% volume decline was a tactical move to reallocate production lines from LSM to higher-margin CM business contracts.


Q: How is Aether strengthening its R&D engine?

A: A new R&D facility featuring approximately 15 labs and 160 fume hoods is scheduled for commissioning in FY28 to handle more complex chemistries.


Q: What is the outlook for the oil and gas segment?

A: This segment has grown from zero to 20% of the business in two years, driven largely by the strategic contract with Baker Hughes

Strategic Outlook

  1. Accelerating phase-wise commissioning of 16 manufacturing blocks at Site 5 (Panoli) to serve as a major platform for pharma, agro, and specialty chemical scaling.
  2. Expanding research facilities and pilot plant infrastructure at Site 1 (Sachin) to accelerate process development for new pipeline molecules.
  3. Working towards a long-term strategic vision to derive 70% of total revenue from exclusive manufacturing and research contracts by FY30.
  4. Planning annual capex allocations (₹300–350 Crores per year) funded through a prudent mix of debt, internal accruals, and customer deposits.
  5. Expanding presence into emerging domains like bio-based polyols, green chemistry, oilfield chemicals, and electronic/semiconductor chemistry applications.


Business Strategy

  1. Prioritizes technically challenging, high-value chemistries and continuous reaction technologies to build strong technological entry barriers against global competitors.
  2. Leverages synergistic revenue streams across Large-Scale Manufacturing (LSM), Contract Research (CRAMS), and Exclusive Custom Manufacturing (CEM) to balance business risks.
  3. Strategically increasing revenue contribution from exclusive contract manufacturing and CRAMS projects to secure long-term, high-margin global supply agreements.
  4. Invests heavily in dedicated R&D and pilot plants to continuously innovate and commercialize new molecules internally before scaling.
  5. Targets first-to-market products in India to replace imports while forming strategic joint manufacturing partnerships with global chemical leaders.


Key Highlights

  1. Revenue from operations grew by 27.25% YoY to reach ₹3,265.57 million in Q1FY27, up from ₹2,566.29 million in Q1FY26. Total full-year revenue for FY26 stood at ₹11,601.41 million.
  2. EBIDTA expanded by 26.58% YoY to ₹1,027.64 million in Q1FY27 compared to ₹811.83 million in Q1FY26. The full-year FY26 EBIDTA reached ₹3,636.36 million.
  3. Operating margins remained exceptionally stable with only a minor dip of 17 basis points YoY, coming in at 31.47% in Q1FY27 versus 31.63% in Q1FY26 (FY26 full-year margin was 31.34%).
  4. Net profit (PAT) increased sharply by 33.25% YoY to ₹628.11 million in Q1FY27 from ₹471.36 million in Q1FY26. Full-year PAT for FY26 stood at ₹2,205.08 million.
  5. PAT margin improved by 87 basis points YoY, rising to 19.23% in Q1FY27 compared to 18.37% in Q1FY26, outpacing the full-year FY26 margin of 19.01%.
  6. Diluted Earnings Per Share (EPS) jumped by 34.46% YoY to ₹4.76 per share in Q1FY27 compared to ₹3.54 in Q1FY26. Full-year FY26 EPS delivered was ₹16.53.


Performance

Q1FY27:


  1. Total Income: ₹ 3265.57 million (27.25%YoY)
  2. EBITDA: ₹ 1027.64 million | EBITDA Margin: 31.47% (-17)
  3. PAT: ₹ 628.11 million | PAT Margin: 19.23% (87)

FY26:

  1. Total Income: ₹ 11601.41 million
  2. EBITDA: ₹ 3636.36 million | EBITDA Margin: 31.34%
  3. PAT: ₹ 2205.08 million | PAT Margin: 19.01%


Disclaimer

This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. Recipients may not receive this report at the same time as other recipients. The information contained herein is from the public domain or sources are believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Opinions expressed are current opinions as of the date appearing on this material only. While we endeavour to update on a reasonable basis, the information discussed in this material, Mr Avinash Gorakshakar is under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Avinash Gorakshakar and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report. This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behaviour of investors or recipients or provide any investment/tax advice. This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis. Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital. Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of Avinash Gorakshakar. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

SEBI REGN NO. INH000001071